Global News

EntreMed announces changes to board of directors, CEO appointment

Friday, April 5, 2013 12:05 PM

The board of directors of EntreMed, a clinical-stage pharmaceutical company focused on cancer, has appointed two new individuals as directors. Joining the board are James Huang and Y. Alexander Wu, Ph.D.

More... »

Foundation Medicine, Agios collaborate on cancer metabolism programs

Friday, April 5, 2013 11:36 AM

Foundation Medicine, a molecular information company, and Agios Pharmaceuticals, a biopharmaceutical company, have formed a multi-year diagnostic partnership for Agios' lead programs in cancer metabolism.

More... »

Quintiles digital properties win two Web Marketing Assoc. awards

Thursday, April 4, 2013 08:00 AM

Quintiles, a provider of biopharmaceutical development and commercial outsourcing services, has received further recognition for the company’s digital communications with two “Internet Advertising Competition” (IAC) awards: one for its corporate website, Quintiles.com, and one for its patient education site, ClinicalResearch.com.

More... »

SynteractHCR hires Bill Pierce and Richard Paul

Thursday, April 4, 2013 08:00 AM

SynteractHCR, a full-service CRO, has hired two new senior executives to support the company's growth on a global scale following its recent merger. SynteractHCR has appointed Bill Pierce as chief information officer and Richard Paul as chief medical officer and vice president medical/regulatory affairs.

More... »

Elan closes Tysabri collaboration transaction with Biogen Idec

Wednesday, April 3, 2013 03:17 PM

Elan, a biotechnology company based in Ireland, has closed its Tysabri (natalizumab) collaboration transaction with Biogen Idec, which was originally announced on February 6, 2013.

More... »

Tetragenetics, Pfizer form collaboration in SionX technology

Wednesday, April 3, 2013 02:48 PM

Tetragenetics, a 2012 Gates Foundation phase II grant recipient and an emerging biotechnology company focused on particle-based vaccines and expression of ion channel drug targets, has entered into a collaboration agreement with an option for an exclusive license with Pfizer.

More... »

Aragen Bioscience, Innovent Biologics collaborate on biotherapeutic product development

Wednesday, April 3, 2013 01:46 PM

Aragen Bioscience, a privately held CRO, and Innovent Biologics, a privately held biopharmaceutical company, have initiated a collaboration for the development of manufacturing cell lines for biotherapeutic product development. Aragen Bioscience will develop robust CHO cell lines and assess critical product quality attributes for various antibodies and protein therapeutics. 

More... »

BRNI partners with Neurotrope BioScience to advance new Alzheimer's discoveries

Wednesday, April 3, 2013 12:14 PM

The Blanchette Rockefeller Neurosciences Institute (BRNI) at West Virginia University has entered into a strategic Joint Product Development and Commercialization Agreement with Neurotrope BioScience, a biotechnology company, in the field of neurodegenerative disease. The central focus of this collaboration will be to advance novel diagnostic and therapeutic technologies developed at BRNI that have shown exceptional promise in both preclinical and clinical models of Alzheimer's disease.

More... »

Crown Bioscience, Horizon Discovery form two-year agreement for in vivo drug discovery model development

Wednesday, April 3, 2013 11:16 AM

Crown Bioscience, a global drug discovery and development service company, and Horizon Discovery, a provider of research tools to support the development of personalized medicines, have signed an exclusive two year collaboration agreement. The relationship is a continuation of a previous collaboration between the two companies.

More... »

William Kennedy of Genentech addresses core operational issues in pediatric trials

Wednesday, April 3, 2013 10:47 AM

Increased pressure to conduct trials in children can be daunting when faced with practical, legal and clinical considerations found only in pediatric trials. Successfully implementing regulations and ethical standards into study conduct requires a comprehensive understanding of the unique concerns raised by ethics committees, investigators and parents.

More... »